- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sony drives use write-once function
Beginning in July, Sony Electronics' new second- and third-generation Advanced Intelligent Tape (AIT) drives will incorporate write-once-read-many (WORM) recording functionality. Specially marked corresponding AIT media will allow for nonrewritable,
Beginning in July, Sony Electronics' new second- and third-generation Advanced Intelligent Tape (AIT) drives will incorporate write-once-read-many (WORM) recording functionality. Specially marked corresponding AIT media will allow for nonrewritable, nonerasable electronic data storage. Building WORM functionality into its AIT-2 and AIT-3 drives and media will help customers address the additional data protection requirements imposed by governmental agencies and certain commercial applications, according to the company. With WORM, the AIT-2 and AIT-3 drives and media can limit accidental or intentional erasure of data, enable time and date authentication, and facilitate quick search and retrieval of archived files, providing extra security protection for stored data. AIT WORM media, which has an estimated 30-year archival life, is identified with a bright red cover, as well as a special graphics design and logotype stamped onto the cartridge. AIT-2 and AIT-3 drives will provide backward compatibility for both WORM and traditional rewritable media.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
